The persistent fatigue that plagues many individuals following a COVID-19 infection—a condition known as Long COVID—may soon have a new treatment option. A recently published clinical trial suggests that fluvoxamine, an antidepressant medication, significantly reduces fatigue and improves quality of life in patients experiencing this debilitating symptom. The findings offer a potential breakthrough for the millions worldwide grappling with the long-term effects of the virus.
Long COVID, characterized by a wide range of symptoms persisting weeks or months after the initial infection, represents a substantial public health challenge. Fatigue is among the most common and disruptive symptoms, hindering the ability of individuals to return to normal daily activities. Until now, treatment options have been largely limited to supportive care, focusing on symptom management and pacing activities. This new research provides the strongest evidence yet for a targeted pharmacological intervention.
The study, published March 31, 2026, in the journal Annals of Internal Medicine, was conducted by an international team led by Dr. Edward Mills of McMaster University in Canada. Researchers found a 99% probability that fluvoxamine was more effective than a placebo in reducing fatigue, a statistically significant result that offers hope to those struggling with this condition. The research team’s findings are particularly encouraging given the lack of established treatments for Long COVID.
Fluvoxamine Shows Promise in Reducing Long COVID Fatigue
The randomized, placebo-controlled trial involved 399 adults who had experienced COVID-19 and continued to suffer from fatigue for at least 90 days post-infection. Participants were divided into three groups: one receiving fluvoxamine, another receiving metformin (a diabetes medication), and a control group receiving a placebo. Over a 60-day period, researchers monitored changes in fatigue severity using a standardized scale (FSS, ranging from 1 to 7, with higher scores indicating greater fatigue).
The results demonstrated a clear benefit for those receiving fluvoxamine. At both 60 and 90 days, the fluvoxamine group reported significantly lower fatigue scores compared to the placebo group. Specifically, the fluvoxamine group showed a 0.43-point reduction in fatigue severity at 60 days and a 0.58-point reduction at 90 days, with the effect becoming more pronounced over time. Notably, the metformin group did not exhibit a significant improvement in fatigue compared to the placebo group. The study was conducted in the Minas Gerais region of Brazil, with collaborative participation from universities including the University of British Columbia (Canada), Stanford University, the University of Pittsburgh, Duke University, and Georgetown University.
[연합뉴스TV 제공]
Safety and Tolerability
Importantly, the study also assessed the safety and tolerability of fluvoxamine. The fluvoxamine group experienced adverse reactions in 20.0% of participants, compared to 28.8% in the metformin group and 29.7% in the placebo group. Serious adverse events were rare across all three groups, suggesting that fluvoxamine is generally well-tolerated. This is a crucial consideration, as many potential treatments for Long COVID are limited by significant side effects.
Beyond Fatigue: Improvements in Quality of Life
The benefits of fluvoxamine extended beyond simply reducing fatigue. Researchers also observed improvements in overall quality of life among participants in the fluvoxamine group. These improvements were measured using various assessment tools, indicating that the medication had a positive impact on multiple aspects of well-being. Dr. Jamie Forrest, the paper’s corresponding author, emphasized the significance of these findings, stating, “This research provides clinicians with the first strong evidence for a drug that may help reduce Long COVID fatigue. Patients want treatments they can try now, and these results take us one step closer to that reality.”
Understanding Long COVID and the Need for Effective Treatments
Long COVID affects an estimated 65 million people globally, posing a significant strain on healthcare systems and impacting the lives of countless individuals. The World Health Organization (WHO) recognizes Long COVID as a complex, multi-system condition that can affect various organs and cause a wide range of symptoms, including fatigue, shortness of breath, cognitive dysfunction (“brain fog”), and chest pain.
Currently, medical guidance for Long COVID largely focuses on supportive care, such as activity management and symptom relief. The lack of proven treatments has left many patients feeling frustrated and without effective options. This study offers a potential turning point, providing a promising avenue for pharmacological intervention.
However, researchers caution that fluvoxamine is not a one-size-fits-all solution. Further research is needed to determine which patients are most likely to benefit from the medication, to elucidate the underlying mechanisms of action, and to explore potential combinations with other therapies. The complex nature of Long COVID, with its diverse biological pathways and symptom presentations, necessitates a personalized approach to treatment.
As Dr. Mills noted, “This is an important step forward for patients who have been waiting for evidence-based treatment. Fluvoxamine showed consistent and meaningful effects, and it is already widely available and well-established in terms of safety.”
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The research team plans to continue investigating the potential of fluvoxamine and other therapies for Long COVID. The next steps include larger-scale clinical trials and studies to identify biomarkers that can predict treatment response. Updates on Long COVID research and treatment guidelines can be found on the Centers for Disease Control and Prevention (CDC) website.
What are your thoughts on this potential new treatment for Long COVID fatigue? Share your comments below, and please share this article with anyone who may find it helpful.
Related reading
